Condition
Central Serous Chorioretinopathy (CSC)
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Not Yet Recruiting2
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07681167Phase 2Not Yet RecruitingPrimary
Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial
NCT07347119Not Yet RecruitingPrimary
Prospective Geometric Analysis of Ultra-Widefield OCTA Characteristics in Central Serous Chorioretinopathy Patients
NCT01256580Not ApplicableWithdrawn
Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
Showing all 3 trials